Limits...
Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system.

Liu LY, Chang LY, Kuo WH, Hwa HL, Lin YS, Jeng MH, Roth DA, Chang KJ, Hsieh FJ - Cancer Inform (2014)

Bottom Line: These data predict malignant events, treatment responses and a novel enhancer of tamoxifen resistance.Taken together, we identify a poor prognosis relevant gene set within the STAT3 network and a robust one in a subset of patients.VEGFA, ABL1, LYN, IGF2R and STAT3 are suggested therapeutic targets for further study based upon the degree of differential expression in our model.

View Article: PubMed Central - PubMed

Affiliation: Department of Agronomy, Biometry Division, National Taiwan University, Taipei, Taiwan.

ABSTRACT
The aberrantly expressed signal transducer and activator of transcription 3 (STAT3) predicts poor prognosis, primarily in estrogen receptor positive (ER(+)) breast cancers. Activated STAT3 is overexpressed in luminal A subtype cells. The mechanisms contributing to the prognosis and/or subtype relevant features of STAT3 in ER(+) breast cancers are through multiple interacting regulatory pathways, including STAT3-MYC, STAT3-ERα, and STAT3-MYC-ERα interactions, as well as the direct action of activated STAT3. These data predict malignant events, treatment responses and a novel enhancer of tamoxifen resistance. The inferred crosstalk between ERα and STAT3 in regulating their shared target gene-METAP2 is partially validated in the luminal B breast cancer cell line-MCF7. Taken together, we identify a poor prognosis relevant gene set within the STAT3 network and a robust one in a subset of patients. VEGFA, ABL1, LYN, IGF2R and STAT3 are suggested therapeutic targets for further study based upon the degree of differential expression in our model.

No MeSH data available.


Related in: MedlinePlus

Clinical impact of STAT3 in two cohorts of ER(+) IDCs analyzed by ANOVA tests.Upper panel, ANOVA test results of STAT3 (15013) mRNA levels in 8 clinical indices—progesterone receptor (PR), HER-2/neu (HER), lymphovascular invasion (LVI), lymph nodal category (lymph node metastasis status-LYM, No. of lymph node metastasis-LNM), age, tumor size, grade (nuclear pleomorphism (NP), mitotic count (MC), tubule formation (TF)) and cancer stage in ER(+) IDCs (90 A; 72 A) (A and B).Lower panel, ANOVA test results of STAT3 (4836) mRNA levels in 8 clinical indices in ER(+) IDCs (90 A; 72 A) (C and D). 15013 and 4836 are the Agilent feature number for STAT3, a STAT3 variant respectively. NP, MC and TF are 3 clinical subindices of the histological grade (grade).
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3921136&req=5

f1-cin-13-2014-021: Clinical impact of STAT3 in two cohorts of ER(+) IDCs analyzed by ANOVA tests.Upper panel, ANOVA test results of STAT3 (15013) mRNA levels in 8 clinical indices—progesterone receptor (PR), HER-2/neu (HER), lymphovascular invasion (LVI), lymph nodal category (lymph node metastasis status-LYM, No. of lymph node metastasis-LNM), age, tumor size, grade (nuclear pleomorphism (NP), mitotic count (MC), tubule formation (TF)) and cancer stage in ER(+) IDCs (90 A; 72 A) (A and B).Lower panel, ANOVA test results of STAT3 (4836) mRNA levels in 8 clinical indices in ER(+) IDCs (90 A; 72 A) (C and D). 15013 and 4836 are the Agilent feature number for STAT3, a STAT3 variant respectively. NP, MC and TF are 3 clinical subindices of the histological grade (grade).

Mentions: ANOVA tests (Fig. 1) indicate a significant decrease in STAT3 mRNA expression levels during mitotic count progression. STAT3 is significantly elevated in ER(+) HER(−) IDCs.


Prognostic features of signal transducer and activator of transcription 3 in an ER(+) breast cancer model system.

Liu LY, Chang LY, Kuo WH, Hwa HL, Lin YS, Jeng MH, Roth DA, Chang KJ, Hsieh FJ - Cancer Inform (2014)

Clinical impact of STAT3 in two cohorts of ER(+) IDCs analyzed by ANOVA tests.Upper panel, ANOVA test results of STAT3 (15013) mRNA levels in 8 clinical indices—progesterone receptor (PR), HER-2/neu (HER), lymphovascular invasion (LVI), lymph nodal category (lymph node metastasis status-LYM, No. of lymph node metastasis-LNM), age, tumor size, grade (nuclear pleomorphism (NP), mitotic count (MC), tubule formation (TF)) and cancer stage in ER(+) IDCs (90 A; 72 A) (A and B).Lower panel, ANOVA test results of STAT3 (4836) mRNA levels in 8 clinical indices in ER(+) IDCs (90 A; 72 A) (C and D). 15013 and 4836 are the Agilent feature number for STAT3, a STAT3 variant respectively. NP, MC and TF are 3 clinical subindices of the histological grade (grade).
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3921136&req=5

f1-cin-13-2014-021: Clinical impact of STAT3 in two cohorts of ER(+) IDCs analyzed by ANOVA tests.Upper panel, ANOVA test results of STAT3 (15013) mRNA levels in 8 clinical indices—progesterone receptor (PR), HER-2/neu (HER), lymphovascular invasion (LVI), lymph nodal category (lymph node metastasis status-LYM, No. of lymph node metastasis-LNM), age, tumor size, grade (nuclear pleomorphism (NP), mitotic count (MC), tubule formation (TF)) and cancer stage in ER(+) IDCs (90 A; 72 A) (A and B).Lower panel, ANOVA test results of STAT3 (4836) mRNA levels in 8 clinical indices in ER(+) IDCs (90 A; 72 A) (C and D). 15013 and 4836 are the Agilent feature number for STAT3, a STAT3 variant respectively. NP, MC and TF are 3 clinical subindices of the histological grade (grade).
Mentions: ANOVA tests (Fig. 1) indicate a significant decrease in STAT3 mRNA expression levels during mitotic count progression. STAT3 is significantly elevated in ER(+) HER(−) IDCs.

Bottom Line: These data predict malignant events, treatment responses and a novel enhancer of tamoxifen resistance.Taken together, we identify a poor prognosis relevant gene set within the STAT3 network and a robust one in a subset of patients.VEGFA, ABL1, LYN, IGF2R and STAT3 are suggested therapeutic targets for further study based upon the degree of differential expression in our model.

View Article: PubMed Central - PubMed

Affiliation: Department of Agronomy, Biometry Division, National Taiwan University, Taipei, Taiwan.

ABSTRACT
The aberrantly expressed signal transducer and activator of transcription 3 (STAT3) predicts poor prognosis, primarily in estrogen receptor positive (ER(+)) breast cancers. Activated STAT3 is overexpressed in luminal A subtype cells. The mechanisms contributing to the prognosis and/or subtype relevant features of STAT3 in ER(+) breast cancers are through multiple interacting regulatory pathways, including STAT3-MYC, STAT3-ERα, and STAT3-MYC-ERα interactions, as well as the direct action of activated STAT3. These data predict malignant events, treatment responses and a novel enhancer of tamoxifen resistance. The inferred crosstalk between ERα and STAT3 in regulating their shared target gene-METAP2 is partially validated in the luminal B breast cancer cell line-MCF7. Taken together, we identify a poor prognosis relevant gene set within the STAT3 network and a robust one in a subset of patients. VEGFA, ABL1, LYN, IGF2R and STAT3 are suggested therapeutic targets for further study based upon the degree of differential expression in our model.

No MeSH data available.


Related in: MedlinePlus